Aster DM Healthcare Ltd

Aster DM Healthcare's subsidiary, Aster DM Multispecialty Hospital Private Limited (ADMPL), has allotted 21,40,000 Series A Compulsorily Convertible Preference Shares (CCPS) and 18,40,000 Series B CCPS to identified investors on a preferential basis. The Series A shares are fully paid-up, while Series B shares are partly paid. Each CCPS can convert into a maximum of 5 equity shares of ADMPL. ADMPL is also seeking additional investment. Aster DM Healthcare's shareholding in ADMPL will remain above 75% on a converted basis.

Aster DM Healthcare reported robust Q4 FY26 standalone financial results, with revenue growing 18% year-on-year to ₹1,182 Cr. Operating EBITDA (excluding Kasaragod) increased by 31% YoY to ₹253 Cr, and normalised PAT (excluding Kasaragod) rose 45% YoY to ₹153 Cr. The merger with Quality Care India Ltd (QCIL) received overwhelming shareholder approval (96.68% in favor) and is on track for completion in Q1 FY2026-27. On a combined proforma basis, Q4 FY26 revenue grew 18% to ₹2,361 Cr, with operating EBITDA up 25% to ₹517 Cr. The combined entity aims to exceed 15,500 beds, positioning it as a top three healthcare provider in India. Performance was driven by strong patient volumes and margin expansion across core hospital, clinics, and labs businesses.

Aster DM Healthcare Ltd's Board of Directors, in a meeting held on April 30, 2026, considered and approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company announced that Deloitte Haskins & Sells, the Statutory Auditors, have issued an unmodified opinion on these results. The financial statements are presented in accordance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Indian Accounting Standards, providing a true and fair view of the company's financial performance.

Aster DM Healthcare's Board of Directors met on April 30, 2026, and approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The company's Statutory Auditors, Deloitte Haskins & Sells, issued an unmodified opinion on these results. The approved results and the auditor's report have been uploaded to the company's website. The meeting commenced at 10:30 AM and concluded at 03:35 PM.

Aster DM Healthcare Ltd has scheduled a Board of Directors meeting on April 30, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.

Aster DM Healthcare Ltd and Malabar Institute of Medical Sciences Limited (MIMS) have revised the total consideration for acquiring a 26% stake in Oyster Green Hybrid Two Private Limited from ₹7.00 Cr to ₹5.80 Cr due to a reduction in the overall project cost. The group has completed the acquisition by investing ₹5.80 Cr in two tranches. Oyster Green Hybrid Two Private Limited is in the business of building, developing, installing, commissioning, operating, and maintaining solar power plants.

Aster DM Healthcare announced the resolution of the nurse strike across its Kerala hospitals. Following extensive engagement with the United Nurses Association and directives from the Hon'ble High Court, which extended the strike deferral until May 31, 2026, all nursing staff have returned to work, and operations have resumed at full capacity. The company incurred an additional revenue loss of ₹5,77,60,948 due to the strike but expects no further losses if the current status quo holds. The High Court proceedings for a final settlement between the Kerala Private Hospital Association and United Nurses Association are ongoing. Aster DM had implemented contingency measures, including mobilizing nurses from other states, to ensure critical services.

Aster DM Healthcare has invested ₹96 crore to expand its Women & Children facility at Aster Whitefield Hospital in Bengaluru. This expansion increases the hospital's bed capacity from 380 to 539 beds, adding 159 dedicated beds. The new 'Aster Women & Children' facility offers comprehensive services including specialized maternity care, water birthing, advanced laparoscopic gynaecology, a child development centre, foetal medicine, a Level 3A NICU, fertility services, and pediatric intensive care. This strategic expansion reinforces Aster DM Healthcare's 12-year legacy in Bengaluru and, combined with other upcoming projects, will boost its total capacity in Karnataka to 2,573 beds, positioning it among the top three private healthcare providers in the state.

Aster DM Healthcare Ltd has declared an interim dividend of Rs. 3/- per equity share for the financial year 2025-26. The company has circulated a communication to shareholders detailing the applicable provisions relating to tax deduction at source (TDS). This communication is also made available on the company's website. The TDS provisions under the Income-tax Act 2025 are explained for both resident and non-resident members.

On March 26, 2026, Aster DM Healthcare Ltd held a Board Meeting where they declared an interim dividend of Rs. 3/- per share for the financial year ending March 31, 2026. The record date for the dividend entitlement is April 3, 2026, and the dividend will be paid within 30 days from the date of declaration. The company will deduct tax at source (TDS) as per the Income Tax Act, 1961, and shareholders are requested to submit necessary documents by April 6, 2026, for appropriate TDS rates.